Objective: Well-conducted meta-analyses (MAs) are considered as one of the best sources of clinical evidence for treatment decision. MA with methodological flaws may introduce bias and mislead evidence users. The aim of this study is to investigate the characteristics and methodological quality of MAs on diabetes mellitus (DM) treatments. Design: Systematic review. Methods: Cochrane Database of Systematic Review and Database of Abstract of Reviews of Effects were searched for relevant MAs. Assessing methodological quality of systematic reviews (AMSTAR) tool was used to evaluate the methodological quality of included MAs. Logistic regression analysis was used to identify association between characteristics of MA and AMSTAR results. Results: A total of 252 MAs including 4999 primary studies and 13,577,025 patients were included. Over half of the MAs (65.1%) only included type 2 DM patients and 160 MAs (63.5%) focused on pharmacological treatments. About 89.7% MAs performed comprehensive literature search and 89.3% provided characteristics of included studies. Included MAs generally had poor performance on the remaining AMSTAR items, especially in assessing publication bias (39.3%), providing lists of studies (19.0%) and declaring source of support comprehensively (7.5%). Only 62.7% MAs mentioned about harm of interventions. MAs with corresponding author from Asia performed less well in providing MA protocol than those from Europe.
Introduction
Diabetes mellitus (DM) refers to a complex metabolic disorder caused by defects in insulin function (1) . It is one of the most common illnesses that increase the global disease burden. There were 387 million DM patients worldwide in 2014 and will increase to 592 million by 2035. In 2014, DM caused 4.9 million of deaths and contributed to 11% of total health expenditure (at least USD 612 billions) among adults (2) . DM is also a significant disease burden in developing countries. For example, the overall prevalence of DM among adult population in China was 11.6% (3) .
With a heavy disease burden worldwide, effective therapies for DM are urgently needed. Systematic review (SR) is an efficient strategy to summarize clinical evidence on treatments for a given disease (4) . In an SR, meta-analysis (MA) is a statistical method that allows quantitative combination of data from different studies, which provides a more precise estimation of treatment effect (4) . However, a biased MA may mislead evidence users, and even do more harm than good (5) . Thus, it is crucial to inform evidence users such as clinicians and researchers on methodological quality while they are using evidence from a MA, so as to make sure that the evidence used for guiding clinical practice or future research is trustworthy.
Methodological quality of MAs on DM has not been comprehensively assessed. This systematic review was conducted to (i) investigate the bibliographical characteristics of MAs on the management of DM, (ii) assess the methodological quality of MAs on DM treatments and (iii) explore the association between bibliographical characteristics and methodological quality of MAs on DM treatments.
Methods

Eligibility criteria
We included publications satisfying the following criteria: (i) study design was SR with at least one MAs and (ii) the MA should focus on treatment effect of DM interventions. Network meta-analyses were excluded.
Literature search
Literature search was conducted in May 2016. The Cochrane Database of Systematic Review and Database of Abstract of Reviews of Effects were searched for potential MAs. Our literature search through these two databases covered both Cochrane reviews and non-Cochrane reviews (6) . No restriction on language or year of publication was applied during the literature search. 'Diabet*' was used as the search keyword.
Literature selection and data extraction
All the retrieved citations were screened and assessed for eligibility. Full texts of potentially eligible publications were retrieved for further assessment. The most updated version was chosen if a MA had been updated. Data on bibliographic characteristics were extracted from each included MA.
Methodological quality assessment
The methodological quality of included MAs was evaluated by the validated Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool (7) . It includes 11 methodological items, which are rated as 'yes', 'no', 'can't answer' or 'not applicable' during the critical appraisal. AMSTAR was chosen as it is proven to be a valid and reliable tool for assessing the methodological rigor of Mas (8, 9) . Literature selection, data extraction and methodological quality evaluation were conducted by two researchers independently. Discrepancies were discussed and resolved by discussion and consensus between the two researchers. If disagreements cannot be resolved, a third assessor was referred to and his judgment was used as final decision.
Data analysis
Data on bibliographic characteristics and methodological quality were analyzed descriptively. Median and range were used for continuous variables. Frequencies were calculated for categorical variables. Methodological quality of included MAs was separately reported among Cochrane and non-Cochrane reviews and different DM types. Respectively, multivariable logistic regression analysis and multinominal logistic regression were 
Results
Results on literature search and basic characteristics of included MAs
Electronic databases search yielded 1586 citations, among which 252 MAs were included in this study ( Fig. 1 Table 2 ). However, MAs on type 1 or 2 diabetes generally showed better performance on AMSTAR than those on gestational DM or multiple types of DM (Table 3) .
Association between bibliographical characteristics and methodological quality of non-Cochrane MAs
Our logistic regressions demonstrated four factors that were associated with several AMSTAR items (Table 4) . Those published more recently had better performance Table 3 Methodological quality of meta-analyses on diabetes mellitus treatments stratified by diabetes mellitus types. 
Discussion
A large number of MAs on the treatment of DM are published, guiding the practice of day-to-day DM care. We identified 252 MAs with 4999 primary studies and more than 13 million participants that assessed the effects of DM interventions. One-seventh of them were Cochrane reviews and half of them were published after 2011. The majority of these MAs focused on pharmacological treatments and T2DM patients. Our results suggested that methodological quality of the MAs included in this study were generally poor, with less than 50% of them satisfying seven out of 11 AMSTAR items. This is consistent with the result of a study that focused on strategies for improving quality of care among DM patients (10) . That study only found that 60% of the 125 included SRs only met four of the 11 AMSTAR methodological criteria. When compared with MAs in other clinical areas, MAs in DM performed no better than those focused on pharmacist health intervention (11), Chinese herbal medicine interventions (12) as well as treatment for chronic obstructive pulmonary disease (13) . Our regression analyses showed that MAs published more recently were significantly related to better performance. Although these indicate methodological progress in the field, there are several key areas that systematic reviewers, evidence users and editors should pay special attention to. First, it has been demonstrated that MAs based solely on published data are likely to be bias as primary studies with positive results are more likely to be published regardless of their rigor (14) . In our study, only 37.3% of MAs attempted to search for gray literature and assessed publication bias respectively. These results indicate that special attention should be paid to both prevention and evaluation of publication bias for future MAs on DM treatments.
Secondly, it is well known that scientific quality of primary studies has a substantial effect on treatment effect estimation (15) . Critical appraisal of included primary study is hence considered as a crucial step for gauging the trustworthiness of MA (16) . However, less than half of the included MAs have assessed scientific quality of included primary studies or have considered that when formulating conclusion. Improvements on these methodological areas are essential in ensuring trustworthiness of MA results.
Thirdly, current studies have suggested that MAs with financial support are less transparent and are less likely to appraise included studies. These MAs usually draw more favorable conclusions for the financially supported intervention (17, 18) . Unfortunately, it is difficult for readers to detect such sponsorship as majority of authors did not state sources of support for both the MA and for each of the included primary studies (10, 12, 13, 19) . Only 7.5% of included MAs reported this information comprehensively. It is noteworthy that 63.5% of included MAs investigated the effects of pharmacological interventions. Bias might be introduced if pharmaceutical industries are involved in these MAs. Readers should also note that 24.4% MAs on pharmacological treatment did not report harm for the intervention, which is a crucial factor for treatment decision-making.
From our results, it seems that Asian research teams neither published as many MAs as European and North American teams: only 21.0% of these MAs had the corresponding authors from Asia. Although MAs conducted in Asia were on par with those conducted elsewhere in most of the AMSTAR items, results from regression analyses showed that MAs with the corresponding authors from Asian countries had worse performance in providing protocol and characteristics of included studies. Asian countries are facing increasing burden of DM and more than 60% of the global DM population is based in Asia (20) . Policymakers in Asia may consider scaling up research capacity in this area, as it is likely that participations from Asian teams would facilitate the searching of regionally relevant evidence for DM management.
Strengths and weaknesses of this study
First, this is the first study that comprehensively assessed the methodological quality of MA on DM treatments, covering both Cochrane and non-Cochrane MAs. Secondly, a validated tool, AMSTAR (8, 9) , was used for critical appraisal of MA in a reliable manner. Thirdly, instead of reporting a total overall score on methodological quality, we reported detailed performance for each AMSTAR item so as to inform specific areas that require improvements in future MAs. One limitation of this study is that methodological quality could only be assessed based on information provided by the MA authors. For example, nearly half (48.4%) of included MAs did not provide information on whether gray literature was searched. This reflects poor adherence of the PRISMA reporting guideline for MA (21) . Another limitation is that AMSTAR did not cover the assessment on the appropriateness of subgroup analysis and sensitivity analysis, of which both are key aspects in the appraisal of MA (22) .
Our results indicate that methodological quality of MAs is variable, and the common perception that MA would provide best evidence is not always true. Clinicians and other evidence users are suggested to assess and consider the methodological quality of MAs while making decision based on evidence generated from them. Future MAs on DM should provide a protocol of the review and comprehensive information on lists of studies and gray literature search. Reporting of conflicts of interests, assessment of publication bias and scientific quality of the included studies as well as consideration of scientific quality when drawing conclusion should also be improved. MA authors are also suggested to report harm of the treatment comprehensively.
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